218 patents
Page 8 of 11
Utility
Process for preparing a composition comprising an enantiomeric excess of greater than or equal to 90% of the (R)-enantiomer of a compound of formula III
13 Apr 21
Jiacheng Zhou, James D. Rodgers, Haisheng Wang
Filed: 10 Jun 19
Utility
Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors
13 Apr 21
Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
Filed: 2 Oct 19
Utility
Salts of an LSD1 inhibitor and processes for preparing the same
6 Apr 21
The present invention relates to processes and intermediates for preparing 3-(cyanomethyl)-3-(4-{[(1R,2S)-2-phenylcyclopropyl]amino}piperidin-1-yl)azetidine-1-sulfonamide, and salts and solid forms thereof, which selectively modulate demethylase.
Zhongjiang Jia, Wayne Han, Yongchun Pan, Timothy Martin, Jiacheng Zhou, Qun Li
Filed: 29 Aug 19
Utility
Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
6 Apr 21
Liangxing Wu, Xiaozhao Wang, Wenqing Yao, Colin Zhang
Filed: 3 Oct 19
Utility
Tricyclic heterocyclic compounds as sting activators
16 Mar 21
The present application provides tricyclic heterocyclic compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Yingda Ye, Zhenwu Li, Wenqing Yao
Filed: 24 May 19
Utility
Bicyclic heterocycles as FGFR inhibitors
16 Mar 21
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Yaping Sun, Wenqing Yao, Liangxing Wu, Meizhong Xu, Ding-Quan Qian, Fenglei Zhang
Filed: 10 Sep 19
Utility
Pyrazolopyridine compounds and uses thereof
2 Mar 21
Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting HPK1 activity and pharmaceutical compositions comprising such compounds.
Oleg Vechorkin, Kai Liu, Alexander Sokolsky, Anlai Wang, Hai Fen Ye, Qinda Ye, Wenqing Yao
Filed: 20 Aug 19
Utility
Imidazo[1,2-B][1,2,4]triazines as c-Met inhibitors
16 Feb 21
The present invention relates to imidazo[1,2-b][1,2,4]triazines that are inhibitors of c-Met and are useful in the treatment of c-Met associated diseases including cancer.
Jincong Zhuo, Chunhong He, Wenqing Yao
Filed: 4 Oct 19
Utility
Tricyclic heterocycles as BET protein inhibitors
16 Feb 21
Andrew P. Combs, Richard B. Sparks, Thomas P. Maduskuie, Jr., James D. Rodgers
Filed: 27 Sep 19
Utility
Heterocyclic compounds as immunomodulators
2 Feb 21
Liangxing Wu, Kaijiong Xiao, Wenqing Yao
Filed: 5 Mar 20
Utility
Processes and intermediates for making a JAK inhibitor
26 Jan 21
This invention relates to processes and intermediates for making {1-{1-[3-fluoro-2-(trifluoromethyl)isonicotinoyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile, useful in the treatment of diseases related to the activity of Janus kinases (JAK) including inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Dengjin Wang, Pingli Liu, Yongzhong Wu, Jiacheng Zhou
Filed: 29 Jan 19
Utility
Benzothiazole compounds and uses thereof
26 Jan 21
Joshua Hummel, Oleg Vechorkin, Alexander Sokolsky, Qinda Ye, Kai Liu, Wenqing Yao
Filed: 7 Aug 19
Utility
Sustained-release dosage forms of ruxolitinib
28 Dec 20
The present invention relates to sustained-release formulations and dosage forms of ruxolitinib, or a pharmaceutically acceptable salt thereof, which are useful in the treatment of Janus kinase-associated diseases such as myeloproliferative disorders.
Yong Ni, Bhavnish Parikh, Krishnaswamy Yeleswaram, Susan Erickson-Viitanen, William V. Williams
Filed: 13 Nov 18
Utility
Heteroaryl amide compounds as sting activators
28 Dec 20
The present application provides heteroaryl amide compounds that activate the STING pathway to produce interferons, which are useful in the treatment of various diseases including infectious diseases and cancer.
Liangxing Wu, Neil Lajkiewicz, Wenqing Yao
Filed: 30 Jul 19
Utility
Topical formulation for a JAK inhibitor
21 Dec 20
This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.
Bhavnish Parikh, Bhavesh Shah, Krishnaswamy Yeleswaram
Filed: 13 Aug 20
Utility
Amorphous solid form of a BET protein inhibitor
7 Dec 20
The present invention relates to an amorphous solid form of (4S)-7-(3,5-dimethylisoxazol-4-yl)-4-pyridin-2-yl-4,5-dihydroimidazo[1,5,4-de][1,4]benzoxazin-2(1H)-one, and processes for its preparation, which is an inhibitor of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and is useful in the treatment of various diseases such as cancer.
Shili Chen, William Frietze, Zhongjiang Jia, Pingli Liu, Jiacheng Zhou
Filed: 28 May 19
Utility
Bicyclic heterocycles as FGFR4 inhibitors
30 Nov 20
The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR4 enzyme and are useful in the treatment of FGFR4-associated diseases such as cancer.
Liangxing Wu, Liang Lu, Ding-Quan Qian, Bo Shen, Wenqing Yao
Filed: 22 Apr 19
Utility
Pyrrolotriazine compounds as TAM inhibitors
23 Nov 20
Yun-Long Li, Xiaozhao Wang, Chunhong He
Filed: 3 Sep 19
Utility
Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
9 Nov 20
The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use.
Chu-Biao Xue, Yun-Long Li, Hao Feng, Ke Zhang
Filed: 14 Nov 19
Utility
Pyrimidinones as PI3K inhibitors
9 Nov 20
The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
Filed: 19 Aug 19